Cell Therapy aims to treat diseases by restoring or altering certain sets of cells, or by using cells to carry a therapy through the body.

CAR-T cell therapy is currently one of Novartis' key focus areas for research and development

Individualized CAR (chimeric antigen receptor) T-cell therapy uses a patient’s own immune system to fight certain types of cancers. A patient’s T-cells are extracted and reprogrammed outside of the body to recognize and fight cancer cells and other cells expressing a particular antigen. CAR-T cell therapies are currently approved by various regulatory bodies to treat certain forms of advanced B-cell blood cancers. Novartis has a deep CAR-T pipeline. Our focus is to broaden the impact of cell therapy in oncology by going deeper in B-cell malignancies, potentially reaching patients in other hematological cancers and solid tumors and researching potential next-generation CAR-Ts that focus on new targets and utilize new technologies.

Scientist working in a lab

Car-T Cell Therapy

Novartis is pioneering the way in cell and gene treatment, setting the standard in patient and caregiver support, safety and efficacy, access, and partnerships with healthcare institutions, local health authorities, and academic institutions.

Tumor cells being attacked by CAR-T

Charging towards the next-generation of CAR-T

With the advancement of T-ChargeTM—a new Novartis-developed platform for investigational pipeline CAR-T cell therapies—we are underscoring our commitment to pioneering cutting-edge innovation in transformative cell therapies.